Related Experiment Videos
Chronic myeloid leukaemia: stem cell derived but progenitor cell driven
Stephen B Marley1, Myrtle Y Gordon
1Department of Haematology, Imperial College Faculty of Medicine, DuCane Road, London W12 0NN, UK.
Clinical Science (London, England : 1979)
|June 22, 2005
Summary
Chronic myeloid leukaemia (CML) involves abnormal stem cell kinetics. Researchers developed a self-renewal assay for myeloid progenitor cells, revealing increased proliferative index in CML patients.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Chronic myeloid leukaemia (CML) is characterized by the p210(BCR-ABL) fusion protein, leading to myeloid lineage expansion.
- The underlying pathology is thought to involve disregulated stem cell kinetics, though less primitive cells also play a role.
Purpose of the Study:
- To investigate the role of stem cell self-renewal in CML pathogenesis.
- To develop and utilize a novel assay for assessing myeloid progenitor cell self-renewal and proliferative index (PI).
Main Methods:
- Development of a self-renewal assay for colony-forming unit-granulocyte/macrophage (CFU-GM).
- Measurement of the proliferative index (PI) in myeloid progenitor cells from CML patients.
Main Results:
- Evidence suggests that in normal hematopoiesis, precursor cells self-renew to maintain homeostasis without stressing stem cells.
- This self-renewal mechanism is dysregulated in CML.
- The developed CFU-GM assay demonstrated an increased PI in the myeloid progenitor cell population of CML patients.
Conclusions:
- The study highlights the dysregulation of progenitor cell self-renewal in CML.
- The novel self-renewal assay provides a versatile tool for in vitro investigation of therapeutic strategies targeting p210(BCR-ABL) expression in CML.